Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $55.55 | 3 | 61.6% |
| Education | $34.56 | 3 | 38.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Taro Pharmaceuticals USA, Inc. | $34.56 | 3 | $0 (2018) |
| Amgen Inc. | $21.67 | 1 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $17.94 | 1 | $0 (2020) |
| Janssen Biotech, Inc. | $15.94 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $21.67 | 1 | Amgen Inc. ($21.67) |
| 2020 | $17.94 | 1 | Novartis Pharmaceuticals Corporation ($17.94) |
| 2018 | $50.50 | 4 | Taro Pharmaceuticals USA, Inc. ($34.56) |
All Payment Transactions
6 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/26/2022 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $21.67 | General |
| Category: Inflammation | ||||||
| 02/28/2020 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Food and Beverage | In-kind items and services | $17.94 | General |
| Category: IMMUNOLOGY | ||||||
| 11/08/2018 | Taro Pharmaceuticals USA, Inc. | TOPICORT (desoximetasone) Topical Spray, 0.25% (Drug), HALOG (Halcinonide Cream, USP) 0.1%, ULTRAVATE (halobetasol propionate) lotion | Education | In-kind items and services | $11.52 | General |
| Category: Dermatology | ||||||
| 11/02/2018 | Janssen Biotech, Inc. | Tremfya (Drug) | Food and Beverage | In-kind items and services | $15.94 | General |
| Category: Immunology | ||||||
| 07/09/2018 | Taro Pharmaceuticals USA, Inc. | HALOG OINTMENT (Halcinonide Ointment, USP) 0.1% (Drug), TOPICORT (desoximetasone) Topical Spray, 0.25%, HALOG (Halcinonide Cream, USP) 0.1% | Education | In-kind items and services | $11.52 | General |
| Category: Dermatology | ||||||
| 06/26/2018 | Taro Pharmaceuticals USA, Inc. | TOPICORT (desoximetasone) Topical Spray, 0.25% (Drug), HALOG OINTMENT (Halcinonide Ointment, USP) 0.1%, ULTRAVATE (halobetasol propionate) lotion | Education | In-kind items and services | $11.52 | General |
| Category: Dermatology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 304 | 307 | $27,094 | $3,658 |
| 2022 | 8 | 2,607 | 4,432 | $405,436 | $182,635 |
| 2021 | 11 | 2,886 | 5,070 | $476,660 | $211,408 |
| 2020 | 12 | 2,989 | 4,953 | $383,852 | $180,183 |
All Medicare Procedures & Services
33 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 152 | 154 | $13,936 | $2,322 | 16.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 152 | 153 | $13,158 | $1,336 | 10.2% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 1,149 | 1,979 | $178,794 | $90,253 | 50.5% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 1,161 | 2,004 | $172,344 | $73,481 | 42.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 113 | 150 | $15,036 | $9,305 | 61.9% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 93 | 100 | $30,000 | $6,751 | 22.5% |
| 17260 | Destruction of cancer skin growth of trunk, arms, or legs, 0.5 cm or less | Office | 2022 | 25 | 28 | $4,200 | $1,770 | 42.1% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2022 | 17 | 17 | $2,414 | $676.56 | 28.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 24 | 30 | $2,400 | $302.27 | 12.6% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2022 | 25 | 124 | $248.00 | $96.39 | 38.9% |
| 17000 | Destruction of skin growth | Office | 2021 | 1,176 | 2,149 | $193,942 | $97,478 | 50.3% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 1,205 | 2,211 | $183,504 | $81,857 | 44.6% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2021 | 151 | 166 | $49,800 | $11,049 | 22.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 121 | 149 | $14,972 | $10,106 | 67.5% |
| 17280 | Destruction of malignant growth (0.5 centimeters or less) of face, ears, eyelids, nose, lips, or mouth | Office | 2021 | 25 | 28 | $8,400 | $3,166 | 37.7% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2021 | 84 | 88 | $10,032 | $2,543 | 25.3% |
| 17260 | Destruction of malignant growth (0.5 centimeters or less) of trunk, arms, or legs | Office | 2021 | 33 | 37 | $5,550 | $2,461 | 44.3% |
| 17271 | Destruction of malignant growth (0.6 to 1.0 centimeters) of scalp, neck, hands, feet, or genitals | Office | 2021 | 11 | 11 | $4,400 | $1,452 | 33.0% |
| 99202 | New patient outpatient visit, total time 15-29 minutes | Office | 2021 | 18 | 18 | $2,514 | $796.09 | 31.7% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 30 | 40 | $3,200 | $361.02 | 11.3% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2021 | 32 | 173 | $346.00 | $138.16 | 39.9% |
| 17000 | Destruction of skin growth | Office | 2020 | 1,206 | 2,032 | $184,096 | $87,794 | 47.7% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 1,237 | 2,112 | $110,198 | $63,320 | 57.5% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2020 | 83 | 85 | $25,300 | $6,494 | 25.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 86 | 114 | $11,400 | $5,481 | 48.1% |
About Dr. Charles Vanmeter, MD
Dr. Charles Vanmeter, MD is a Dermatopathology healthcare provider based in Frederick, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1063472009.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Charles Vanmeter, MD has received a total of $90.11 in payments from pharmaceutical and medical device companies, with $21.67 received in 2022. These payments were reported across 6 transactions from 4 companies. The most common payment nature is "Food and Beverage" ($55.55).
As a Medicare-enrolled provider, Vanmeter has provided services to 8,786 Medicare beneficiaries, totaling 14,762 services with total Medicare billing of $577,885. Data is available for 4 years (2020–2023), covering 33 distinct procedure/service records.
Practice Information
- Specialty Dermatopathology
- Location Frederick, MD
- Active Since 03/24/2006
- Last Updated 07/08/2007
- Taxonomy Code 207ND0900X
- Entity Type Individual
- NPI Number 1063472009
Products in Payments
- TOPICORT (desoximetasone) Topical Spray, 0.25% (Drug) $23.04
- Otezla (Drug) $21.67
- COSENTYX (Biological) $17.94
- Tremfya (Drug) $15.94
- HALOG OINTMENT (Halcinonide Ointment, USP) 0.1% (Drug) $11.52
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.